Download PDF
Der Klinikarzt 2020; 49(03): 91-96
DOI: 10.1055/a-1101-8661
Schwerpunkt
© Georg Thieme Verlag Stuttgart · New York

Management gastrointestinaler Blutungen unter Antikoagulation

Interventionelle und medikamentöse Herangehensweise
Benjamin Meier
1   Klinik für Innere Medizin, Gastroenterologie, Hämato-Onkologie, Pneumologie, Diabetologie und Infektiologie, Klinikum Ludwigsburg, Ludwigsburg
,
Christian Wolpert
2   Klinik für Innere Medizin, Kardiologie, Nephrologie und internistische Intensivmedizin, Klinikum Ludwigsburg, Ludwigsburg
,
Karel Caca
1   Klinik für Innere Medizin, Gastroenterologie, Hämato-Onkologie, Pneumologie, Diabetologie und Infektiologie, Klinikum Ludwigsburg, Ludwigsburg
› Author Affiliations
Further Information

Publication History

Publication Date:
17 March 2020 (online)

Also available at
    Permissions and Reprints

ZUSAMMENFASSUNG

Die endoskopische Therapie bei gastrointestinalen Blutungen ist hoch effektiv und sicher, auch unter Einnahme von Antikoagulanzien. Das technische Vorgehen unterscheidet sich nicht vom Vorgehen bei fehlender Einnahme von Antikoagulanzien, wobei z. B. der Stellenwert einer primären OTSC („over-the-scope clip“, Ovesco Endoscopy)-Applikation bei Hochrisikopatienten noch untersucht werden muss. Das Management der Antikoagulation unterscheidet sich zwischen den unterschiedlichen Präparaten und der zugrundeliegenden Indikation und muss dem individuellen Risiko angepasst werden. Thrombozytenaggregationshemmer sollten maximal für die Intervention pausiert und früh wieder verabreicht werden. Das Management unter dualer Plättchenhemmung oder Triple-Therapie ist zwingend interdisziplinär abzusprechen. Bei Niedrigrisikosituation kann die duale Therapie in der Regel fortgeführt werden. Bei vitaler Blutung unter Vollantikoagulation ist eine Antagonisierung empfohlen, bei nicht vitaler Blutung ist diese abhängig vom endoskopischen Erfolg. Die Vollantikoagulation sollte frühestmöglich, in der Regel nach ca. 7 Tagen, wieder aufgenommen werden (Ausnahmen: mechanische Herzklappen, frisch implantierte Bioklappen, sehr hohes Thromboembolierisiko).

 

  • Literatur

  • 1 Eikelboom JW, Connolly SJ, Bosch J. et al Bleeding and New Cancer Diagnosis in Patients With Atherosclerosis. Circulation 2019; 140: 1451-1459
    CrossrefPubMedGoogle Scholar
  • 2 Blatchford O, Murray WR, Blatchford M. A risk score to predict need for treatment for upper-gastrointestinal haemorrhage. Lancet 2000; 356: 1318-1321
    CrossrefPubMedGoogle Scholar
  • 3 Cheng DW, Lu YW, Teller T. et al A modified Glasgow Blatchford Score improves risk stratification in upper gastrointestinal bleed: a prospective comparison of scoring systems. Aliment Pharmacol Ther 2012; 36: 782-789
    CrossrefPubMedGoogle Scholar
  • 4 Gotz M, Anders M, Biecker E. et al [S2k Guideline Gastrointestinal Bleeding – Guideline of the German Society of Gastroenterology DGVS]. Z Gastroenterol 2017; 55: 883-936
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Sachar H, Vaidya K, Laine L. Intermittent vs continuous proton pump inhibitor therapy for high-risk bleeding ulcers: a systematic review and meta-analysis. JAMA Intern Med 2014; 174: 1755-1762
    CrossrefPubMedGoogle Scholar
  • 6 Adler DG, Leighton JA, Davila RE. et al ASGE guideline: The role of endoscopy in acute non-variceal upper-GI hemorrhage. Gastrointest Endosc 2004; 60: 497-504
    CrossrefPubMedGoogle Scholar
  • 7 Tekant Y, Goh P, Alexander DJ. et al Combination therapy using adrenaline and heater probe to reduce rebleeding in patients with peptic ulcer haemorrhage: a prospective randomized trial. Br J Surg 1995; 82: 223-226
    CrossrefPubMedGoogle Scholar
  • 8 Laine L, Jensen DM. Management of patients with ulcer bleeding. Am J Gastroenterol 2012; 107: 345-360
    CrossrefPubMedGoogle Scholar
  • 9 Lau JY, Sung JJ, Lam YH. et al Endoscopic retreatment compared with surgery in patients with recurrent bleeding after initial endoscopic control of bleeding ulcers. N Engl J Med 1999; 340: 751-756
    CrossrefPubMedGoogle Scholar
  • 10 Calvet X, Vergara M, Brullet E. et al Addition of a second endoscopic treatment following epinephrine injection improves outcome in high-risk bleeding ulcers. Gastroenterology 2004; 126: 441-450
    CrossrefPubMedGoogle Scholar
  • 11 Lo CC, Hsu PI, Lo GH. et al Comparison of hemostatic efficacy for epinephrine injection alone and injection combined with hemoclip therapy in treating high-risk bleeding ulcers. Gastrointest Endosc 2006; 63: 767-773
    CrossrefPubMedGoogle Scholar
  • 12 Marmo R, Rotondano G, Piscopo R. et al Dual therapy versus monotherapy in the endoscopic treatment of high-risk bleeding ulcers: a meta-analysis of controlled trials. Am J Gastroenterol 2007; 102: 279-289
    CrossrefPubMedGoogle Scholar
  • 13 Park CH, Lee SJ, Park JH. et al Optimal injection volume of epinephrine for endoscopic prevention of recurrent peptic ulcer bleeding. Gastrointest Endosc 2004; 60: 875-880
    CrossrefPubMedGoogle Scholar
  • 14 Barkun AN, Martel M, Toubouti Y. et al Endoscopic hemostasis in peptic ulcer bleeding for patients with high-risk lesions: a series of meta-analyses. Gastrointest Endosc 2009; 69: 786-799
    CrossrefPubMedGoogle Scholar
  • 15 Chung IK, Ham JS, Kim HS. et al Comparison of the hemostatic efficacy of the endoscopic hemoclip method with hypertonic saline-epinephrine injection and a combination of the two for the management of bleeding peptic ulcers. Gastrointest Endosc 1999; 49: 13-18
    CrossrefPubMedGoogle Scholar
  • 16 Ljubicic N, Budimir I, Biscanin A. et al Endoclips vs large or small-volume epinephrine in peptic ulcer recurrent bleeding. World J Gastroenterol 2012; 18: 2219-2224
    CrossrefPubMedGoogle Scholar
  • 17 Schmidt A, Golder S, Goetz M. et al Over-the-Scope Clips Are More Effective Than Standard Endoscopic Therapy for Patients With Recurrent Bleeding of Peptic Ulcers. Gastroenterology 2018; 155: 674-686
    CrossrefPubMedGoogle Scholar
  • 18 Cahyadi O, Bauder M, Meier B. et al Effectiveness of TC-325 (Hemospray) for treatment of diffuse or refractory upper gastrointestinal bleeding – a single center experience. Endosc Int Open 2017; 5: E1159-E1164
    Article in Thieme ConnectPubMedGoogle Scholar
  • 19 Chen YI, Wyse J, Lu Y. et al TC-325 hemostatic powder versus current standard of care in managing malignant GI bleeding: a pilot randomized clinical trial. Gastrointest Endosc 2019 Aug 19
    PubMedGoogle Scholar
  • 20 Seshasai SR, Wijesuriya S, Sivakumaran R. et al Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials. Arch Intern Med 2012; 172: 209-216
    CrossrefPubMedGoogle Scholar
  • 21 Cote R, Zhang Y, Hart RG. et al ASA failure: does the combination ASA/clopidogrel confer better long-term vascular protection?. Neurology 2014; 82: 382-389
    CrossrefPubMedGoogle Scholar
  • 22 Caldeira D, Barra M, Ferreira A. et al Systematic review with meta-analysis: the risk of major gastrointestinal bleeding with non-vitamin K antagonist oral anticoagulants. Aliment Pharmacol Ther 2015; 42: 1239-1249
    CrossrefPubMedGoogle Scholar
  • 23 Gu ZC, Wei AH, Zhang C. et al Risk of Major Gastrointestinal Bleeding With New vs Conventional Oral Anticoagulants: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2019 Jun 11
    PubMedGoogle Scholar
  • 24 Holster IL, Valkhoff VE, Kuipers EJ, Tjwa ETTL. New oral anticoagulants increase risk for gastrointestinal bleeding: a systematic review and meta-analysis. Gastroenterology 2013; 145: 105-112
    CrossrefPubMedGoogle Scholar
  • 25 Hansen ML, Sorensen R, Clausen MT. et al Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med 2010; 170: 1433-1441
    PubMedGoogle Scholar
  • 26 Choudari CP, Rajgopal C, Palmer KR. Acute gastrointestinal haemorrhage in anticoagulated patients: diagnoses and response to endoscopic treatment. Gut 1994; 35: 464-466
    CrossrefPubMedGoogle Scholar
  • 27 Rubin TA, Murdoch M, Nelson DB. Acute GI bleeding in the setting of supratherapeutic international normalized ratio in patients taking warfarin: endoscopic diagnosis, clinical management, and outcomes. Gastrointest Endosc 2003; 58: 369-373
    PubMedGoogle Scholar
  • 28 Gralnek IM, Dumonceau JM, Kuipers EJ. et al Diagnosis and management of nonvariceal upper gastrointestinal hemorrhage: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 2015; 47: a1-46
    Article in Thieme ConnectPubMedGoogle Scholar
  • 29 Karstensen JG, Ebigbo A, Aabakken L. et al Nonvariceal upper gastrointestinal hemorrhage: European Society of Gastrointestinal Endoscopy (ESGE) Cascade Guideline. Endosc Int Open 2018; 6: E1256-E1263
    Article in Thieme ConnectPubMedGoogle Scholar
  • 30 Valgimigli M, Bueno H, Byrne RA. et al 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2018; 39: 213-260
    CrossrefPubMedGoogle Scholar
  • 31 Biondi-Zoccai GG, Lotrionte M, Agostoni P. et al A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. Eur Heart J 2006; 27: 2667-2674
    CrossrefPubMedGoogle Scholar
  • 32 Burger W, Chemnitius JM, Kneissl GD, Rucker G. Low-dose aspirin for secondary cardiovascular prevention – cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation – review and meta-analysis. J Intern Med 2005; 257: 399-414
    CrossrefPubMedGoogle Scholar
  • 33 Qureshi W, Mittal C, Patsias I. et al Restarting anticoagulation and outcomes after major gastrointestinal bleeding in atrial fibrillation. Am J Cardiol 2014; 113: 662-668
    CrossrefPubMedGoogle Scholar
  • 34 Sengupta N, Feuerstein JD, Patwardhan VR. et al The risks of thromboembolism vs. recurrent gastrointestinal bleeding after interruption of systemic anticoagulation in hospitalized inpatients with gastrointestinal bleeding: a prospective study. Am J Gastroenterol 2015; 110: 328-335
    CrossrefPubMedGoogle Scholar
  • 35 Witt DM, Delate T, Garcia DA. et al Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for gastrointestinal tract bleeding. Arch Intern Med 2012; 172: 1484-1491
    CrossrefPubMedGoogle Scholar
  • 36 Kido K, Scalese MJ. Management of Oral Anticoagulation Therapy After Gastrointestinal Bleeding: Whether to, When to, and How to Restart an Anticoagulation Therapy. Ann Pharmacother 2017; 51: 1000-1007
    CrossrefPubMedGoogle Scholar
  • 37 Sengupta N, Marshall AL, Jones BA. et al Rebleeding vs Thromboembolism After Hospitalization for Gastrointestinal Bleeding in Patients on Direct Oral Anticoagulants. Clin Gastroenterol Hepatol 2018; 16: 1893-1900
    CrossrefPubMedGoogle Scholar
  • 38 Connolly SJ, Crowther M, Eikelboom JW. et al Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors. N Engl J Med 2019; 380: 1326-1335
    CrossrefPubMedGoogle Scholar
  • 39 Van der Wall SJ, Lopes RD, Aisenberg J. et al Idarucizumab for Dabigatran Reversal in the Management of Patients With Gastrointestinal Bleeding. Circulation 2019; 139: 748-756
    CrossrefPubMedGoogle Scholar
  • 40 Honickel M, Braunschweig T, Rossaint R. et al Reversing Dabigatran Anticoagulation with Prothrombin Complex Concentrate versus Idarucizumab as Part of Multimodal Hemostatic Intervention in an Animal Model of Polytrauma. Anesthesiology 2017; 127: 852-861
    CrossrefPubMedGoogle Scholar
  • 41 Frontera JA, Bhatt P, Lalchan R. et al Cost comparison of andexanet versus prothrombin complex concentrates for direct factor Xa inhibitor reversal after hemorrhage. J Thromb Thrombolysis 2020; 49: 121-131
    CrossrefPubMedGoogle Scholar